This document updates previous documents and provides a condensed overview of the existing information. It aims to support healthcare professionals in developing optimal approaches to managing patients struggling with hyperuricemia (HU) and its related health conditions. The intention is to enhance the decision-making process for healthcare professionals in their daily clinical activities. However, it is important to note that the responsible healthcare provider should make the final decisions regarding patient care, considering what is most appropriate in the given context. Particular attention will be given to the latest advancements in this field. First, the focus herein,was on: — pointing to the need to standardize the definition of HU; — paying attention to HU in patients with chronic kidney disease (CKD); — paying attention to HU values associated with the risk of various ardiovascular diseases (CVD); — focusing on new medications supporting HU treatment with allopurinol in patients at increased cardiovascular risk.

Borghi, C., Domienik-Karłowicz, J., Tykarski, A., Filipiak, K.j., Jaguszewski, M.j., Narkiewicz, K., et al. (2024). Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2023 update. CARDIOLOGY JOURNAL, 31(1), 1-14 [10.5603/cj.98254].

Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2023 update

Borghi C
Primo
Conceptualization
;
2024

Abstract

This document updates previous documents and provides a condensed overview of the existing information. It aims to support healthcare professionals in developing optimal approaches to managing patients struggling with hyperuricemia (HU) and its related health conditions. The intention is to enhance the decision-making process for healthcare professionals in their daily clinical activities. However, it is important to note that the responsible healthcare provider should make the final decisions regarding patient care, considering what is most appropriate in the given context. Particular attention will be given to the latest advancements in this field. First, the focus herein,was on: — pointing to the need to standardize the definition of HU; — paying attention to HU in patients with chronic kidney disease (CKD); — paying attention to HU values associated with the risk of various ardiovascular diseases (CVD); — focusing on new medications supporting HU treatment with allopurinol in patients at increased cardiovascular risk.
2024
Borghi, C., Domienik-Karłowicz, J., Tykarski, A., Filipiak, K.j., Jaguszewski, M.j., Narkiewicz, K., et al. (2024). Expert consensus for the diagnosis and treatment of patients with hyperuricemia and high cardiovascular risk: 2023 update. CARDIOLOGY JOURNAL, 31(1), 1-14 [10.5603/cj.98254].
Borghi, C; Domienik-Karłowicz, J; Tykarski, A; Filipiak, Kj; Jaguszewski, Mj; Narkiewicz, K; Barylski, M; Mamcarz, A; Wolf, J; Mancia, G
File in questo prodotto:
File Dimensione Formato  
Borghi C_Expert consensus for the diagnosis_Cardiol J. 2024.pdf

accesso aperto

Tipo: Versione (PDF) editoriale / Version Of Record
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione 297.26 kB
Formato Adobe PDF
297.26 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/1009583
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 16
  • ???jsp.display-item.citation.isi??? 15
social impact